Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-738-3 | CAS number: 110-13-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Neurotoxicity
Administrative data
- Endpoint:
- neurotoxicity: sub-chronic oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1995
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- publication
- Title:
- Axonal Atrophy Is a Specific Component of 2,5-Hexandedione Peripheral Neuropathy
- Author:
- E.J. Lehning, K.S. Dyer, B.S. Jortner, R.M. LoPachin
- Year:
- 1 995
- Bibliographic source:
- Toxicology and Applied Pharmacology, 135, 1995, 58-66
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Hexane-2,5-dione
- EC Number:
- 203-738-3
- EC Name:
- Hexane-2,5-dione
- Cas Number:
- 110-13-4
- Molecular formula:
- C6H10O2
- IUPAC Name:
- hexane-2,5-dione
- Test material form:
- not specified
- Details on test material:
- Aldrich Chemical Company, 97% purity
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- Taconic Farms, GErmantown, NY, 250-275 g bw, Purina Rodent Lab Chow, water ad lib.,
Administration / exposure
- Route of administration:
- oral: drinking water
- Vehicle:
- water
- Details on exposure:
- 0.4 % (w/v), maximum concentration tolerated without severe reduction in daily water consumption
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 77, 86 and 103 days
- Frequency of treatment:
- daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0.37 g/kg/d
Basis:
actual ingested
- No. of animals per sex per dose:
- one dose, male animals only
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Index of hexanedione-induced neurological deficits: hindlimb weakness as indicated by performance on a treadmill.
Rats were sacrificed when developping hindlimb weakness. Sciatic nerve and posterior tibial nerve were analyzed.
Examinations
- Observations and clinical examinations performed and frequency:
- Index of hexanedione-induced neurological deficits: hindlimb weakness as indicated by performance on a treadmill.
- Neurobehavioural examinations performed and frequency:
- Sciatic nerve and posterior tibial nerve were analyzed after sacrifice.
- Sacrifice and (histo)pathology:
- ketamine and xylazine
- Positive control:
- No
- Statistics:
- ANOVA
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- reduced body weight gain
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- approx. 30 % reduction
- Behaviour (functional findings):
- effects observed, treatment-related
- Description (incidence and severity):
- hindlimb weakness
- Neuropathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Sciatic nerve and posterior tibial nerve
Effect levels
- Dose descriptor:
- other: axonal atrophy
- Effect level:
- ca. 370 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male
- Remarks on result:
- other:
Applicant's summary and conclusion
- Conclusions:
- Axonal atrophy is a specific, functionally relevant neuropathic component of hexanedione neuropathy.
Male SD rats receiving 370 mg/kg bw day (oral application) developped hindlimb weakness after 77-103 days.
Examination of the sciatic nerve and posterior tibial nerve show axonal swelling and atrophy.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.